Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

The Harrison County Community Foundation recently announced Samantha Carr as the recipient of the 2025 Lilly Endowment ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...